With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
JNJ trades against a final fair-value range of $244.50-$419.09, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
A severe stress test assumes complete loss of exclusivity on key blockbuster drugs without adequate pipeline replacement, compounded by a massive cash drain from talc litigation settlements. Operating margins compress to the low 20s, and the market violently re-rates the multiple to 12x, dropping the stock towards $150.
Settlements and ongoing liabilities breach the ring-fenced strategy, draining >$15B in free cash flow and triggering credit downgrades.
Biosimilar penetration accelerates faster than modeled, wiping out billions in high-margin revenue over 24 months with no pipeline offset.
Aggressive legislative action imposes strict price caps on top oncology/immunology assets, structurally impairing mature ROIC and terminal margins.
| Line item | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Revenue | $79.99B | $85.16B+6.5% | $88.82B+4.3% | $94.19B+6.0% | +5.6% |
| Gross profit | $55.39B | $58.61B | $61.35B | $63.94B | +4.9% |
| Operating income | $21.01B | $22.01B | $21.25B | $25.60B | +6.8% |
| Net income | $17.94B | $35.15B+95.9% | $14.07B-60.0% | $26.80B+90.5% | +14.3% |
| EPS (diluted) | $6.73 | $13.72 | $5.79 | $11.03 | +17.9% |
| EBITDA | $26.61B | $23.32B | $24.78B | $41.06B | +15.6% |
| R&D | $14.14B | $15.09B | $17.23B | $14.67B | +1.2% |
| SG&A | $20.25B | $21.51B | $22.87B | $23.68B | +5.4% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| R&D yield deteriorating (fewer late-stage pipeline approvals per $1B spent). | Monitor | Deterioration versus the report thesis |
| Operating margins sustained below 25%. | Monitor | Deterioration versus the report thesis |
